Chao Wu1,2, Ding-Bang Chen1,2, Li Feng2,3, Xiang-Xue Zhou2,4, Ji-Wei Zhang5, Hua-Jing You1,2, Xiu-Ling Liang1,2, Zhong Pei1,2, Xun-Hua Li1,2. 1. Department of Neurology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China. 2. Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, Guangzhou, Guangdong, China. 3. Department of Neurology Intensive Care Unit, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China. 4. Department of Neurology, The East Area of the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China. 5. Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Abstract
AIMS: To detect specific oculomotor deficits in preclinical stage of spinocerebellar ataxia type 3 (SCA3) and evaluate whether these abnormalities prove useful as potential biomarkers of disease progression. METHODS: A Chinese cohort of 56 patients with SCA3, including 12 preclinical carriers of SCA3 (pre-SCA3) and 44 manifest SCA3, and 26 healthy control individuals were recruited. We performed a detailed investigation on central oculomotor performance including fixation, gaze, smooth pursuit, prosaccade, and antisaccade using video-oculography. RESULTS: Common oculomotor features of pre-SCA3 included square-wave jerk during central fixation and gaze holding, impaired vertical smooth pursuit, slow upward saccade, and increased antisaccade error rate. In our SCA3 cohort, all oculomotor parameters were correlated with the score of the Scale for the Assessment and Rating of Ataxia, whilst some of them were correlated with disease duration. CONCLUSION: This study showed that a series of neuropathological changes reflected by oculomotor abnormalities appeared preferentially in preclinical stage of SCA3. Accordingly, objective oculomotor preclinical signs may be useful to detect the optimum time-point for therapeutic interventions in future clinical trials of SCA3. Larger and longitudinal data are warranted to confirm our results.
AIMS: To detect specific oculomotor deficits in preclinical stage of spinocerebellar ataxia type 3 (SCA3) and evaluate whether these abnormalities prove useful as potential biomarkers of disease progression. METHODS: A Chinese cohort of 56 patients with SCA3, including 12 preclinical carriers of SCA3 (pre-SCA3) and 44 manifest SCA3, and 26 healthy control individuals were recruited. We performed a detailed investigation on central oculomotor performance including fixation, gaze, smooth pursuit, prosaccade, and antisaccade using video-oculography. RESULTS: Common oculomotor features of pre-SCA3 included square-wave jerk during central fixation and gaze holding, impaired vertical smooth pursuit, slow upward saccade, and increased antisaccade error rate. In our SCA3 cohort, all oculomotor parameters were correlated with the score of the Scale for the Assessment and Rating of Ataxia, whilst some of them were correlated with disease duration. CONCLUSION: This study showed that a series of neuropathological changes reflected by oculomotor abnormalities appeared preferentially in preclinical stage of SCA3. Accordingly, objective oculomotor preclinical signs may be useful to detect the optimum time-point for therapeutic interventions in future clinical trials of SCA3. Larger and longitudinal data are warranted to confirm our results.
Authors: Heike Jacobi; Till-Karsten Hauser; Paola Giunti; Christoph Globas; Peter Bauer; Tanja Schmitz-Hübsch; László Baliko; Alessandro Filla; Caterina Mariotti; Maria Rakowicz; Perine Charles; Pascale Ribai; Sandra Szymanski; Jon Infante; Bart P C van de Warrenburg; Alexandra Dürr; Dagmar Timmann; Sylvia Boesch; Roberto Fancellu; Rafal Rola; Chantal Depondt; Ludger Schöls; Elzbieta Zdzienicka; Jun-Suk Kang; Susanne Ratzka; Berry Kremer; Dennis A Stephenson; Béla Melegh; Massimo Pandolfo; Sophie Tezenas du Montcel; Johannes Borkert; Jörg B Schulz; Thomas Klockgether Journal: Cerebellum Date: 2012-03 Impact factor: 3.847
Authors: Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner Journal: Arch Neurol Date: 2006-06
Authors: H Jacobi; M Rakowicz; R Rola; R Fancellu; C Mariotti; P Charles; A Dürr; M Küper; D Timmann; C Linnemann; L Schöls; O Kaut; C Schaub; A Filla; L Baliko; B Melegh; J-S Kang; P Giunti; B P C van de Warrenburg; R Fimmers; T Klockgether Journal: Cerebellum Date: 2013-06 Impact factor: 3.847
Authors: T Schmitz-Hübsch; M Coudert; P Bauer; P Giunti; C Globas; L Baliko; A Filla; C Mariotti; M Rakowicz; P Charles; P Ribai; S Szymanski; J Infante; B P C van de Warrenburg; A Dürr; D Timmann; S Boesch; R Fancellu; R Rola; C Depondt; L Schöls; E Zdienicka; J-S Kang; S Döhlinger; B Kremer; D A Stephenson; B Melegh; M Pandolfo; S di Donato; S Tezenas du Montcel; T Klockgether Journal: Neurology Date: 2008-08-06 Impact factor: 9.910
Authors: Hilary W Heuer; Jacob B Mirsky; Erwin L Kong; Bradford C Dickerson; Bruce L Miller; Joel H Kramer; Adam L Boxer Journal: Neurology Date: 2013-08-28 Impact factor: 9.910
Authors: Timothy J Shakespeare; Diego Kaski; Keir X X Yong; Ross W Paterson; Catherine F Slattery; Natalie S Ryan; Jonathan M Schott; Sebastian J Crutch Journal: Brain Date: 2015-04-19 Impact factor: 13.501
Authors: Gabriel Vasata Furtado; Camila Maria de Oliveira; Gabriela Bolzan; Jonas Alex Morales Saute; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim Journal: Genet Mol Biol Date: 2019-06-10 Impact factor: 1.771
Authors: Gustavo L Franklin; Carlos Henrique F Camargo; Alex T Meira; Giovana M Pavanelli; Sibele S Milano; Francisco B Germiniani; Nayra S C Lima; Salmo Raskin; Orlando Graziani Povoas Barsottini; José Luiz Pedroso; Fernanda Aparecida Maggi; Vitor Tumas; Pedro Manzke de Carvalho; Ana Carolina de Oliveira; Bárbara Braga; Laura Cristina Souza; Rachel Paes Guimarães; Luiza Gonzaga Piovesana; Íscia Teresinha Lopes-Cendes; Paula Christina de Azevedo; Marcondes Cavalcante França; Alberto Rolim Muro Martinez; Hélio A G Teive Journal: Front Neurol Date: 2020-11-12 Impact factor: 4.003